Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease

New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. I...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver Vol. 13; no. 6; pp. 604 - 616
Main Author: Moon, Won
Format: Journal Article
Language:English
Published: Korea (South) Editorial Office of Gut and Liver 15.11.2019
Gastroenterology Council for Gut and Liver
거트앤리버 소화기연관학회협의회
Subjects:
colitis
crohn disease
Fecal Microbiota Transplantation
Humans
inflammatory bowel diseases
Inflammatory Bowel Diseases - drug therapy
Review
Stem Cell Transplantation
therapy
ulcerative
내과학
Crohn disease
Therapy
Inflammatory bowel diseases
Colitis, ulcerative
ISSN:1976-2283, 2005-1212, 2005-1212
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. In spite of their long-term effectiveness, many patients do not respond to or cannot sustain treatment with these drugs, which have various side effects. Therefore, the development of new drugs targeting specific pathways in the pathogenesis of IBD has become necessary. Some novel biologics and small molecule drugs have shown potential in IBD clinical trials, providing safe and effective results. In addition, clinicians are now trying to target the dysbiotic microbiome of patients with IBD using fecal microbiota transplantation. New tools such as stem cells have also been developed. The available therapeutic options for IBD are expanding rapidly. In the next few years, physicians will face an unprecedented number of options when choosing the best treatments for patients with IBD. This review provides an overview of recent advances in IBD treatment options.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1976-2283
2005-1212
2005-1212
DOI:10.5009/gnl19019